VMware Maintains at Buy and 4 Stock Analyses Buzzing Today

Biogen Idec Inc. (NASDAQ:BIIB): Credit Suisse has increased its peak revenue estimate for BG12 to $4 billion from $3 billion in 2018. The firm believes that BG12 will “revolutionize” the MS market, and it keeps its Outperform rating on the stock.

Medtronic, Inc. (NYSE:MDT): After it conducted checks with U.S. electrophysiologists, Oppenheimer has gained encouragement regarding the outlook for 2012 volume growth of ICDs/CRT-Ds and key products. The firm keeps its Outperform rating and raised its target to $48 from $45 on the stock.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Gap Inc.’s (NYSE:GPS) strong September comp sales gains has influenced CLSA to increase Gap estimates due to improved merchandising and reduced cost goods. Shares have a Buy rating.

SodaStream International Ltd. (NASDAQ:SODA) U.S. business is believed by JPMorgan to represent lower than 5 percent of the company’s current market cap, seen as too cheap. The firm believes that a more reasonable value for the business would be about $300 million to $400 million, which gives the stock a pricing in the high $40’s to low $50’s. JPMorgan reiterates its Overweight rating and $50 price target on the stock.

VMware, Inc. (NYSE:VMW) is believed by JMP Securities to have closed several million dollar deals as it gained a number of significant federal contracts during Q3. The firm keeps its Outperform rating and a $125 target on the stock.

Don’t Miss: How Confident is Apple of the iPad Mini?